Latest hair loss news, treatment information
Overall status of new technology as of October 2018
8384
95
Updated October 2018 This post contains a list of the most surviving and related hair regeneration treatments developed and known. They can be called hair loss treatments, hair growth treatments, hair loss treatments, and alopecia treatments. The treatments in this guide are anticipated evaluations based on the potential of hair growth efficacy and when the treatment can be released to the open market. # 1 is the most appropriate. The rating of the list can always change depending on the information available.
1. Shiseido / Replicel - Replicel's hair growth therapy, RCH-01, involved culturing human hair follicle cells and then injecting them back into the scalp. First, remove a small punch biopsy from a healthy hair follicle of a person. The specific cells are then dissected from follicles and cultured in growth media. Cells are replicated in millions and then injected back into the human scalp. Here is a short video of the procedure. Replicel has been involved in a number of activities over the years to advance the RCH-01 treatment into a global success. Initially, Replicel partnered with Shiseido, the world's fourth-largest cosmetics company. In May 2014, Shiseido opened a huge biotechnology facility in Japan to accelerate the launch of Replicel's hair technology, RCH-01. The efforts are in perfect alignment with Japan's new legislation designed to expedite the testing process of stem cell technology. In other words, Japan is an ideal place to launch new cellular-based technologies and get them to market quickly. To clarify, Shiseido and Replicel are separate companies. Replicel granted Shiseido the right to bring RCH-01 to the world through Japan's fast regulatory pathway. Shiseido has a scientist working on a separate hair regeneration technique using iPS cells. Treatment with iPS cells can be further advanced and potentially cause infinite amounts of hair regrowth.
Key Content: Shiseido is currently piloting Replicel's RCH-01 in Japan for market approval by the end of 2018. Replicel is planning its own RCH-02 phase of clinical trials to be conducted after 2019. Pathways of North America. Repicel's Lee Buckler told Pollicle Thought he estimated the September/October 2018 announcement from Shiseido.
Status: Shiseido's Japanese trial began in the third quarter of 2016. Depending on the date of completion of the trial, which has not been disclosed, processing may be possible in 2019.
2. Fidia Pharma - Trinov a.k.a. "Brotzu Motion" is a formula created by Dr. Giovanni Brotzu, an Italian vascular surgeon. Dr. Brozzu discovered this hair growth therapy while testing medication to treat vascular failure in diabetics. In a blood vessel study in which Broz Joe's research team tests modifications to people's scalp, it was found that the prescription of the drug makes hair back on the patient's legs. The test has proven to be worthwhile. This formula has been modified to use DGLA instead of PGE1 because DGLA is not classified as a drug and much less clinical trials are needed to be approved for hair growth. The ingredients of this lotion are DGLA, carnitine, S-equol, and cationic liposomes. Fidia Pharma, an Italian-based pharmaceutical company, has acquired the right to manufacture a Brotzu formulation for hair and appears to be conducting clinical studies with a lotion for AGA patients. The study has been completed, and Fidia said the treatment should be available by the end of 2018. Point: Fidia Pharma purchased the right to develop this hair growth lotion after viewing preliminary data. Dr. Brotzu also released a photo of a young girl with alopecia who used lotion and achieved impressive results in 2016. Fidia Pharma announced in September 2018 that it would sell Dr Brotzu's formula under the name "Trinov" and launch it in Italy at the end of 2018.
Status: to begin selling through the Italian boutique website in early December 2018.
3. Allergan (Kythera Acid) - Setipiprant is an oral drug or medicine. Specifically, Cetifent is a prostaglandin D2 receptor 2 (PTGDR2) antagonist. Setipiprant was originally developed for medical purposes except hair growth and has undergone clinical trials for these indications. After George Cotsarellis discovered that Prostaglandin D2 plays an important role in hair growth at UPENN, Kythera initiated a preclinical trial at Cotsarellis' office to determine whether PTGDR2 antagonists are worth developing as a hair growth treatment. About two years later, Kythera announced that it had acquired the right to use its hair growth promoter, setipiprant, from Cotsarellis. Since then, big pharmaceutical company Allergan has acquired Kythera and setipiprant with it. Setipiprant is currently in a 2A clinical trial.
Note: Setipiprant has already undergone Phase 3 clinical trials in the United States. This allows the product to start in phase 2 in the clinical trial process for androgenic alopecia. Because it is an oral drug, it can be easily managed and complied with.
Status: Phase 2A clinical trial completed and data will be released in the second half of 2018.
4. Histogen - Histogen's Hair Stimulating Complex (HSC660) is a cell-conditioned medium extracted from neonatal cells grown under embryo-like conditions. This is an injectable serum used to stimulate the growth of existing hair follicles on the human scalp as well as new hair follicles. The treatment was first published around 2008 and many people are eager to be released to the market. HSC has shown visual evidence of its efficacy and has shown much in clinical trials. This treatment has been applied to both men and women and is said to be effective in regenerating hair in temples, including the scalp. Early HSC products were purified over the past few years to contain less cellular impurities and more intensive growth factors in the first few years. In May 2018, Histogen received an IND from the U.S. FDA to test HSC in female alopecia.
Note: This is a treatment that has a very high appeal due to its ease of application. Theoretically, you can go inside, get a shot, and go out. You don't need to harvest your own cells and you don't need to inject them again like other cell-based treatments. Having made news or progress due to a long drought, Histogen announced a Phase 1 women's trial in the United States and told a news publication in San Diego that Phase 3 trials for commercialization are taking place in Mexico.
CONDITIONS: Men's AGA Phase III trial has begun in Mexico, according to Gail Naughton. A Phase 1 clinical trial of female alopecia began in July 2018 in Southern California.
5. RiverTown Therapeutics Inc - RT1640 consists of minoxidil, cyclosporine-A, and a novel molecule RT175. The compound was developed by the founder of RiverTown Therapeutics Inc., David Weinstein MD, PhD. In the Phase 1 clinical trial, 100% of those treated showed satisfactory hair growth, while a few showed significant hair regeneration. RiverTown Therapeutics Showed Fantastic Hair Growth Results In Pollicle Thought. The three agents of RT1640 act in the distinct pathway of AGA and exert synergistic effects, promoting the growth and retention of follicles. In addition, RT1640 reactivates melanocyte progenitor cells that give hair color, so RT1640 is said to restore pigment to some of the regenerated hair. Interestingly, RT1640 has been brought to life through the founder's personal interest in restoring hair growth. RiverTown was featured in a popular article in New Yorker magazine in June 2018.
Attention: The results of these RT1640s are the most important hair regeneration results I've witnessed in topical treatment. RT1640 can not only re-cut hair, but also restore pigment to some of the regenerating hair. The three drugs that make up RT1640 have a strong safety profile and have all previously been tested in clinical trials.
Status: We are currently seeking investment or strategic partners to begin our Phase 1B/2A study in 2018. 6. Samumed - SM04554 is a small molecule topical solution that activates the Wnt pathway to grow hair. In March 2016, Samumed announced the highly anticipated Phase 2 results in the American Academy of Dermatology. The second phase of the results were mixed reactions from online growth enthusiasts, but the conclusion was that hair grew bigger at the trial. Approximately, hair density increased by 10% overall in the most responsive group with SM04554. Prior to the completion of the study, Samumed began a second phase 2 study with biopsy analysis of the scalp to better understand the hair growth of molecules. Initial Phase 2 trials draw the conclusion that the drug does not include a "dose response" in patients using it. In other words, adding more drugs to the patient's anatomy won't produce more results. Finding the "right dose" and dosage is important for this drug to do its best.
Point: Samumed completed critical start-up phase 2 within approximately 2 years, starting with clinical trials. Samumed announced in August 2018 that it would move hair growth by topic for market approval.
CONDITION: In Q3 2018, Samumed announced the completion of an investigator meeting for a subsequent Phase 3 clinical trial of SM04554.
7. Cassiopea - Breezula is a topical anti-androgen developed for AGA treatment. Unlike other anti-androgenic agents that block the body's DHT production, Breezeula works by blocking the function of DHT to bind to androgen receptors in hair follicles. Breezeula has also been found to reduce prostaglandin D2 (PGD2) production in the skin, a biological compound that has been shown to inhibit hair growth to increased levels. The next reported data from Breezeula's Phase 2 dose trial will be very welcome and will surface in late 2018/early 2019. Cortexolone-17α-propionate, an active ingredient in Breezeula, is also being administered by Cassiopea to treat acne. In July 2018, Cassiopea issued a press release explaining positive data in the interim phase of its Phase 2 clinical trial.
Of interest: Antioxidants with no hormonal side effects (reportedly). The company says the drug does not interfere with the androgenic profile of patients being treated. Cassiopea said the initial Phase 2 results produced by Breezeula at 6 months are comparable to oral Propecia results in a 12-month clinical trial.
CONDITIONS: A Phase 2 dose measurement study is underway in Germany, where full data is expected to be released in early 2019. Cassiopea announced interim positive data from its July 2018 trial. Coming to market in 2022.
8. Follicum - Follicum is a Swedish biotechnology company that develops human peptides to promote hair growth and inhibit hair growth. The leading candidate peptide of Pollicum is called FOL-005. It is recommended to be called FOL-S-005 when stimulating hair growth. Interestingly, this peptide is being tested for use in hair growth and inhibition. According to Jan Allenfall, CEO of Pollicum, various factors will determine what growth/impeding effects will be achieved from FOL-005. Some of these factors include the dosage, the method of administration, and the type of follicle to be treated. Clearly, Pollicum will learn more about the mechanism of action of peptides through early clinical trials. FOL-S-005 will be commercialized as a topical solution under the Pollicum website. Phase 2 clinical trial of FOL-005 is expected to be completed in January 2017. As Pollicum previously mentioned that he expects to use hair inhibitors in this safety trial, we should wait to see what kind of data we should acquire from this study.
Point of Interest: Pollicum published a graph of preclinical experiment results for Follow-S-005's Pollicle Thought. The hair growth effect of this peptide was accidentally detected in mice in 2004. In other words, it took 11 years to perform R&D in this finding. Pollicum has been working with renowned head researcher Ralph Paus since 2012 for research and development. They began a human trial in early 2016 that secured two major manufacturing partners for peptide technology.
Condition : Phase 2A exam was completed in August 2018.Data from this test will be released in October 2018.
9. Tsuji-Riken / Organ Technologies - Dr. Takashi Tsuji runs the world's most advanced stem cell laboratory at the Riken Institute in Japan. Thankfully, he set out to work on growing his hair using stem cells at R&D and later secured a major partner to help him with his work. In mid-2016 it was announced that Riken would launch a joint venture with electronics company Kyocera and regenerative medicine company Organ Technologies to market Dr Tsuji's hair regeneration treatment. In the joint venture, Kyocera will develop cell processing units, while RIKEN and Organ Technologies will be responsible for stem cell culture and manipulation, production processes and preclinical trial implementation. The treatment involves extracting a small number of hair follicles from the donor scalp area of a person and then separating the two types of cells from the papilla cells of the bulge and the hair follicles, which are epidermal cells. These cells are cultured, expanded, and combined to create a follicle "germ" or "follicular primordium." Once the follicle is ready, the plant can be transplanted back into a human scalp to grow hair. Summary: Tsuji has been studying hair follicles for many years, and her strategic partner will finally introduce her hair growth therapy to the world. Organ Technology will now develop the world's fastest market-approved treatment for cellular therapy in Japan. In June 2018, RIKEN announced that their laboratory was moving towards animal studies of newly refined protocols. Start a human ordeal.
Status: Currently, we are conducting research and development with the goal of launching the market in 2020 if it goes well.
10. Aclaris Therapeutics - Aclaris acquired the right to treat alopecia and androgenic alopecia using JOP inhibitors from Angela Christiano's company, Vixen, in early 2016. JAKinibs showed amazing results in alopecia. Sometimes the entire hair grows back. Preclinical studies have shown that JAKinibs may have the ability to benefit all types of hair growth. The human ordeal to address this potential was finally initiated by Aclaris in the second quarter of 2018.
JAK inhibitors have shown the ability to push follicles into the growth or "growth" phase. It was published by Angela Christiano. Aclaris is currently testing topical JAK inhibitors and is also developing new "soft" topical JAK inhibitors for AGA trials.
Status: Currently testing ATI-502 in a Phase 2 public label study for AGA, both men and women, which began in April 2018. Data should be presented in this study at the beginning of 2019.
11. Followa - Known as one of the quietest companies on the horizon of hair growth treatments, Followa is also one of the most anticipated. Followa was founded in 2007 and science is based on creating microscapes on the scalp for hair production. Since Pollica's original clinical trial (which did not produce the desired results), Pollica has continued research and development that combines microwound with new compounds to increase follicle formation. Followa's cure turned out to be the abbreviation "RAIN." RAIN treatment is a treatment package that will be used at home consisting of 1) microwound treatment combined with clinical-occurring application compounds 2) topical formulations and application devices. The company has also developed a smartphone application that helps users track their home treatment routines.
Attention: Followa co-founder Dr. George Cotsarellis is one of the household names in the hair follicle research field and holds a patent on hair growth. Pollica, which takes about a decade to develop, plans to begin a pivotal clinical trial in the next few years, and if results are pending, Pollica's hair growth therapy could be approved to the market shortly after the clinical trial. In October 2016, Followa launched a new website to showcase aspects of therapy and smartphone apps. RAIN treatment is a simple and tolerable procedure, although not yet fully disclosed.
Condition: Aimed at Central FDA clearance trials in 2019. 12. HairClone - HairClone is a British biotechnology company that regenerates hair through papillary cells on cultured skin. The company has constructed an interesting business model, leveraging scientific innovation and favorable regulatory pathways. HairClone aims to bank a few follicles in a deep freeze-storage facility and then periodically use the follicles for years to make cell cocktails and re-inject them into the scalp. This is an innovative approach to cell hair growth therapy and makes it easy for patients to perform repetitive procedures. HairClone expects cell therapy to weaken and rejuvenate existing hair follicles, as well as form new hair follicles. The company's key leadership includes Dr. Paul Kemp, Dr. Vincent Ranford, and well-known head surgeon Drs. Bessam과 Nilofer Farjo. A news video describing the hairclone procedure was reported in 2017.
Areas of Interest: HairClone's founder was responsible for the first company to attempt hair regeneration through cell therapy (Intercytex) in late 2000. HairClone has formed a strong scientific advisory committee, including renowned researcher Dr. Claire Higgins. This procedure is expected to involve extracting 50 follicles via FUE, placing those follicles in cold preservation, and the only surgery available in the following year as needed. HairClone estimates that patients want to undergo follow-up every two to three years to maintain optimal hair health. The company plans to announce a crowdfunding campaign sometime in 2018.
Condition : Perform current cell expansion process and establish hair replication protocol. The official announcement of the company's crowdfunding campaign is scheduled for October 2018.
On the horizon: Dr. Angela Chrisiano & Dr. Colin Jahoda (Rapunzel) - the most prominent name in the study of hair follicles. Dr. Jahoda's latest public research has focused on 3D skin papilla culture, and Dr. Christiano has frequently appeared in news headlines through his work on JAK inhibitors and hair growth. Dr. Christiano has recently sold JAK IP to Acharis Therapeutics to conduct clinical trials that JAK inhibitors use to treat AGA and alopecia. Furthermore, the two researchers teamed up on Christiano's new prototype, "Rapunzel," to develop treatments to regenerate hair using cultured hair cells. Christiano recently said, "We think mice can grow hair, but we don't have tomorrow, but we can also do it with human hair."
Dr. Jahoda transplanted his hair cells into his wife's arm and discovered that his cells grew on her hair in 1999. In other words, the person has experience in cell hair growth research. In addition, Jahoda and Christiano were issued a new patent related to 3D follicle culture in January 2017.
Condition: in preclinical research.
Hair Transplant Photos & Reviews
1 / 14
Comments 95